Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer

Kassouf, Wassim; Black, Peter C.; Tuziak, Tomasz; Bondaruk, Jolanta; Lee, Sangkyou; Brown, Gordon A.; Adam, Liana; Wei, Caimiao; Baggerly, Keith A.; Bar‐Eli, Menashe; McConkey, David J.; Czerniak, Bogdan; Dinney, Colin P.

doi:10.1016/j.juro.2007.08.087

Cited by 86 publications

(79 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also pointed out that HER2 status in BC varies from 9% to over 80% in regards to protein overexpression and 0-32% regarding gene amplification (4-76 and 3-9% in NMIBC, respectively, in Table 1); furthermore, conflicting data exist regarding its prognostic relevance in BC [18,24,[26][27][28][29][30][31][32][33][34][35][36]. The reason for such variability of HER2 positivity is multifactorial, resulting from (a) tumor heterogeneity, with case series featuring varying tumor stages and histological grades (and different grading systems), (b) the diversity of methods used to assess HER status (amplification detection versus overexpression detection), (c) the technique used (polymerase chain reaction [PCR], in situ hybridization [ISH] and immunohistochemistry [IHC]) to assess HER2 status, and also (d) the specific definition given to HER2 "positivity" [24,37,38]; ethnic or geographic differences may account for further reasons [39].…”

Section: Her2 and Bcmentioning

confidence: 99%

See 1 more Smart Citation

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial. A comprehensive review of the literature has been carried out. An electronic search of databases from PubMed, Scopus, Google Scholar was implemented. The search terms were: “BC,” “bladder carcinoma,” “bladder neoplasm,” “human epidermal growth factor 2,” “HER2,” “HER-2,” “c-erbB-2,” “c-erbB2,” “erbB-2,” “erbB2,” “neu,” “marker,” “biomarker,” and “prognosis”. Results of the review consented to (a) summarize the available data on HER2 a predictor of recurrence and/or progression free survival on univariate and multivariate analysis, (b) explore the related issues in assessing HER2 status on these tumor samples, since they may severely impair its predictive function, and (c) report the state-of-the art of HER2 as a putative therapeutic target in BC and especially non-muscle invasive BC. HER2 stands out for being a prognostic factor as well as a therapeutic target in various cancers. Data from the literature concerning its use in BC provide conflicting results, probably due to the inherent complexity of BC biology. Efforts should be made to establish a suitable tumor-specific scoring system, and to assess single drugs’ efficacy in well-designed clinical trials.

show abstract

Section: Her2 and Bcmentioning

confidence: 99%

“…On the other hand, Gandour-Edwards et al [31] reported an increased DSS in patients who overexpressed HER2 when treated with paclitaxel-based CT for advanced BC. Finally, some other studies failed to detect any correlation between HER2 status and survival outcomes [36,47,69,84].…”

Section: Survival Outcomesmentioning

confidence: 99%

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…14 Tumor invasion and histologic grade were classified according to the TNM staging and the 1997 World Health Organization grading system, respectively. 15 The tumors were grouped based on stage into noninvasive (Ta-T1a) and invasive (T1b-T4) as described previously. 16 The patient population studied consisted of 34 cases of noninvasive low-grade (grade 1-grade 2) papillary tumors, 9 cases of noninvasive highgrade (grade 3) papillary tumors, 13 cases of invasive high-grade (grade 3) papillary tumors, and 89 cases of invasive high-grade (grade 3) nonpapillary tumors.…”

Section: Patients and Tissue Samplesmentioning

confidence: 99%

Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer

Inamoto

Czerniak

Dinney

et al. 2009

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:Nurr1 belongs to a novel class of orphan nuclear receptors (the NR4A family). The authors have previously shown that Nurr1 is important in carcinogenesis. In the current study, they examined the clinicopathologic relevance of expression patterns of Nurr1 in bladder tumors.METHODS:Nurr1 expression was determined using immunohistochemical staining in a bladder cancer tissue array (145 tumors). Tumors were classified according to Nurr1 protein levels in both cytoplasm and nucleus. Disease‐specific survival and recurrence‐free survival were investigated by Kaplan‐Meier analysis and Cox proportional hazards analysis in multivariate models and correlated with variables such as tumor stage, growth pattern, and clinical outcome (recurrence and survival). In vitro, Nurr1 was examined for its role in bladder cancer cell proliferation and migration using small interfering RNA silencing.RESULTS:Nurr1 expression in tumor cells correlated with increasing tumor stage and invasive growth pattern. Disease‐specific survival was significantly shorter in patients whose tumors demonstrated a high level of cytoplasmic Nurr1 compared with those with lower levels of cytoplasmic Nurr1 expression. Furthermore, cytoplasmic Nurr1 expression level was found to be an independent predictor of disease‐specific survival (odds ratio, 4.894; P < .001). In vitro, silencing of endogenous Nurr1 attenuated the migration of bladder cancer cells.CONCLUSIONS:The expression of Nurr1 in the cytoplasm correlates with adverse outcome and is an independent prognostic marker for tumor progression and survival in patients with bladder cancer. This might represent a novel target in bladder cancer therapy. Cancer 2010. © 2010 American Cancer Society.

show abstract

“…Overexpression of EGFR, and amplification/overexpression of ERBB2 is more common in muscle-invasive tumors, but their prognostic significance is controversial [57]. Agents with EGFR, HER-2, and mixed pharmacologies have all entered clinical trials in bladder cancer patients.…”

Section: Targeting Growth Factor Receptors and Signal Transduction Pamentioning

confidence: 99%

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

Dovedi

Davies

2009

Cancer Metastasis Rev

View full text Add to dashboard Cite

Urothelial cell carcinoma is the fifth most common cancer and the costliest to treat. This is largely because of all new cases, about 70% present as superficial disease and this while rarely fatal, tends to recur, requiring long-term follow-up and repeat interventions. The standard of care, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and approximately 30% of patients either fail to respond to treatment or suffer recurrent disease within 5 years. Muscle-invasive bladder cancer is life threatening, showing modest chemosensitivity, and usually requires radical cystectomy. Although bladder cancer is fairly well-genetically characterized, clinical trials with molecularly targeted agents have, in comparison to other solid tumors such as lung, breast and prostate, been few in number and largely unsuccessful, with no new agents being registered in the last 20 years. Hence, bladder cancer represents a considerable opportunity and challenge for molecularly targeted therapy.

show abstract

Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer

Cited by 86 publications

References 16 publications

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

Contact Info

Product

Resources

About